Maxwellia key facts
as of Oct 2026- Developer of a consumer healthcare platform designed to increase access to medicines by transforming prescription-only drugs into over-the-counter brands.
- Maxwellia is valued at approximately $29.9M as of Oct 2026 (last reported valuation).
- It has raised $27.5M; the latest was Later Stage VC ($4.2M) in Jun 2025.
- Notable investors include Innovate UK, British Business Bank, Praetura Ventures, Alderley Park, Catapult Ventures — 13 tracked in total.
- Status: Privately Held (backing).
Maxwellia's last reported valuation, Jun 2025. Nothing priced has surfaced since.
- ·The complete investor list: 13 names
- ·Watch Maxwellia: the Monday email on marks, rounds and moves
Maxwellia funding rounds
No funding rounds for Maxwellia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Maxwellia
13+Maxwellia valuation
Maxwellia's last reported valuation was $29.9 million in Jun 2025. No priced round, secondary trade or fund mark has surfaced since.
Maxwellia investors
13 investors are on record for Maxwellia, including Innovate UK, British Business Bank, Praetura Ventures and Alderley Park.
About Maxwellia
Developer of a consumer healthcare platform designed to increase access to medicines by transforming prescription-only drugs into over-the-counter brands. The company offers a streamlined and efficient conversion process through its DynamicSwitch method, enabling consumers to take control of their health and contributing to innovation in the global healthcare market.
- Sector
- Healthcare
- HQ
- Macclesfield, United Kingdom
- Founded
- 2013
- Employees
- 9
- Website
- maxwellia.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.